Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia.

Pharmacotherapy - 1 Jun 2018

Ward Kristen M, Yeoman Larisa, McHugh Cora, Kraal A Zarina, Flowers Stephanie A, Rothberg Amy E, Karnovsky Alla, Das Arun K, Ellingrod Vicki L, Stringer Kathleen A

Abstract excerpt

STUDY OBJECTIVE: Patients with schizophrenia are known to have higher rates of metabolic disease than the general population. Contributing factors likely include lifestyle and atypical antipsychotic (AAP) use, but the underlying mechanisms are unknown. The objective of this study was to identify metabolomic variability in adult patients with schizophrenia who were taking AAPs and grouped by fasting insulin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Fatty Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Insulin

Share to Magnetic Resonance Spectroscopy

Share to Metabolomics

Share to Phenotype

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 29722909
DOI: 10.1002/phar.2119
PMCID: PMC6014920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia.PMID 29722909Read ↗

Metabolome in schizophrenia and other psychotic disorders: a general population-based studySemantic proximity Read ↗

Prevalence and factors associated of metabolic syndrome in first- treatment drug-naïve schizophrenia patients: a large-scale cross- sectional studySemantic proximity Read ↗

Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.Semantic proximity Read ↗

No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample.Semantic proximity Read ↗

Phenotypic characteristics in metabolically healthy but obese patients with schizophrenia.Semantic proximity Read ↗

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome.Semantic proximity Read ↗

Atypical antipsychotic (AAP)-induced metabolic toxicity : study of mechanisms, biomarkers and reversal strategiesSemantic proximity Read ↗

The Multidimensional Nature of Metabolic Syndrome in Schizophrenia: Lessons from Studies of One-Carbon Metabolism and DNA MethylationSemantic proximity Read ↗

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic TreatmentSemantic proximity Read ↗

Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatmentSemantic proximity Read ↗

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?Semantic proximity Read ↗

Schizophrenia shows a unique metabolomics signature in plasma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.